| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 02/02/2011 | CN1899615B Preparation for the prophylaxis of restenose |
| 02/02/2011 | CN101965197A Use of s-adenosylmethionine (sam) and superoxide dismutase (sod) for the preparation of medicaments for the treatment of alzeimer's disease |
| 02/02/2011 | CN101965196A Sugar chain-related gene and use thereof |
| 02/02/2011 | CN101961493A Ace2 activation for treatment of heart, lung and kidney disease and hypertension |
| 02/02/2011 | CN101961492A Ezetimibe compound preparation for treating dyslipidemia |
| 02/02/2011 | CN101961491A Novel blood pressure and blood fat reduction composition |
| 02/02/2011 | CN101961490A Compound composition containing nitrobrate |
| 02/02/2011 | CN101961489A Method for establishing experimental model for subclinical hepatic encephalopathy (SHE) |
| 02/02/2011 | CN101961484A Prostate secretory protein 94/57 (Psp94/57), analogous polypeptides thereof for preparing medicaments for eliminating drug (therapy) resistance of tumor, and application thereof |
| 02/02/2011 | CN101961418A Double-controlled release, high-dosage and low-irritation capsaicin compound transdermal patch |
| 02/02/2011 | CN101961333A A thiazolidinedione derivative and its use as antidiabetic |
| 02/02/2011 | CN101961306A Preparation method of low melting point drug solid dispersion |
| 02/02/2011 | CN101669899B Sustained-release implant taking maize protein as main framework material or matrix and use thereof |
| 02/02/2011 | CN101273970B Microemulsion type preparation of glucocorticoid medicine for nasal cavity |
| 02/01/2011 | US7879966 pH-sensitive polymer |
| 02/01/2011 | US7879908 reducing number of episodes of postinfarction heart failure in patients by intravenously administering L-carnitine or salt thereof within 6 hours of onset of symptoms of acute myocardial infarction to patients in need thereof, at an initial dose of 9 grams a day, in combination with glucose solution |
| 02/01/2011 | US7879881 Piperidinyl compounds that selectively bind integrins |
| 02/01/2011 | US7879874 3(R)-1-Phenethyl-(9[H]-xanthene-9-carbonyloxy)-1-azoniabicyclo[2.2.2] octane quaternary salt with a mono- or polyvalent anion; antimuscarinic agents used to treat chronic obstructive pulmonary disease, chronic bronchitis, bronchial hyperreactivity, asthma, or rhinitis |
| 02/01/2011 | US7879872 Compositions comprising multiple bioactive agents, and methods of using the same |
| 02/01/2011 | US7879868 Use of imatinib (glivec,sti-571) to inhibit breast cancer resistance protein (BCRP)-mediated resistance to therapeutic agents |
| 02/01/2011 | US7879832 Use of the combination of ciclesonide and antihistamines for the treatment of allergic rhinitis |
| 02/01/2011 | US7879831 Enhanced drug delivery in transdermal systems |
| 02/01/2011 | US7879823 Topical anti-cancer compositions and methods of use thereof |
| 02/01/2011 | US7879817 Non-steroidal anti-inflammatory drugs bound to hyaluronic acid through a covalent bond via a spacer having a biodegradable region and disease-modifying anti-rheumatic drugs; salicylic acid, aspirin, mefenamic acid, tolfenamic acid; arthritis, suppress inflammation and pain; parenteral, topical |
| 02/01/2011 | US7879810 That contain unmethylated cytosine-guanine (CpG) dinucleotides; stimulate an immune response and to redirect a Th2 response to a Th1 response; use with vaccines |
| 02/01/2011 | US7879604 Intervertebral disk repair, methods and devices therefor |
| 02/01/2011 | US7879577 Modified polypeptides stabilized in a desired conformation and methods for producing same |
| 02/01/2011 | US7879547 Method of detecting the presence of asthma or allergies in a patient |
| 02/01/2011 | US7879366 Halogenated composition, method for preparing same and uses thereof |
| 02/01/2011 | US7879357 Pharmaceutical composition in the form of a hydrogel for transdermal administration of active ingredients |
| 02/01/2011 | US7879342 Vaccine adjuvant and making and using the same |
| 02/01/2011 | US7879323 Antibodies to fibroblast growth factor-like polypeptides |
| 02/01/2011 | CA2641952C Treatment of early stage idiopathic pulmonary fibrosis |
| 02/01/2011 | CA2505918C A liposome having bound albumin and peg |
| 02/01/2011 | CA2484935C Amide derivatives as inhibitors of the enzymatic activity of renin |
| 02/01/2011 | CA2483002C New pharmaceutical composition |
| 02/01/2011 | CA2481468C Medicaments containing betamimetic drugs and a novel anticholinesterase drug |
| 02/01/2011 | CA2477881C Formoterol superfine formulation |
| 02/01/2011 | CA2453442C Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases |
| 02/01/2011 | CA2446812C Novel sulfonate-substituted pyrazolopyridine derivatives |
| 02/01/2011 | CA2442917C Combination therapy comprising glucose reabsorption inhibitors and ppar modulators |
| 02/01/2011 | CA2430755C Method of producing a partial or complete active ingredient coating on and in implants and onplants |
| 02/01/2011 | CA2388377C Medication for the treatment of chronic fatigue syndrome and related symptoms |
| 02/01/2011 | CA2313653C Prevention and/or treatment of allergic conditions |
| 02/01/2011 | CA2274902C Submucosa extracts |
| 02/01/2011 | CA2219978C Method for inhibiting neoplastic disease in mammals |
| 02/01/2011 | CA2189143C A method of modifying angiotensin receptor activity for treatment of premenstrual syndrome and mediation of pain |
| 02/01/2011 | CA2125472C A method for generation of antibodies to cell surface molecules |
| 01/27/2011 | WO2011011199A1 Combination therapies with ck2 modulators |
| 01/27/2011 | WO2011011092A1 Methods and compositions to reduce oxidative stress |
| 01/27/2011 | WO2011011027A1 Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases |
| 01/27/2011 | WO2011010691A1 Polyion complex comprising phd2 expression inhibiting substance |
| 01/27/2011 | WO2011010456A1 EXTERNAL PREPARATION CONTAINING NSAIDs AND METHOD FOR PRODUCING THE EXTERNAL PREPARATION |
| 01/27/2011 | WO2011009601A1 Cell protection in dialysis patients by administration of a creatine compound |
| 01/27/2011 | WO2010130462A3 Phosphate-free pharmaceutical composition for the treatment of glaucoma |
| 01/27/2011 | US20110021603 TRPM-2 Antisense Therapy |
| 01/27/2011 | US20110021528 Novel hydroxamates as therapeutic agents |
| 01/27/2011 | US20110021508 Methods for Alzheimer's Disease Treatment and Cognitive Enhancement |
| 01/27/2011 | US20110021502 Use of cholinesterase inhibitors for treating vascular depression |
| 01/27/2011 | US20110021478 Combinations comprising antimuscarinic agents and pde4 inhibitors |
| 01/27/2011 | US20110021477 Combinations comprising antimuscarinic agents and corticosteriods |
| 01/27/2011 | US20110021476 Combinations comprising antimuscarinic agents and pde4 inhibitors |
| 01/27/2011 | US20110021441 Conjugate comprising p21 protein for the treatment of cancer |
| 01/27/2011 | US20110021437 Method for reducing pain with ziconotide and baclofen |
| 01/27/2011 | US20110021436 Method for reducing pain with ziconotide and morphine |
| 01/27/2011 | US20110021417 Compositions comprising oligosaccharides |
| 01/27/2011 | US20110021413 Methods of suppressing microglial activation |
| 01/27/2011 | US20110021365 Nucleic Acid Binding Compounds Containing Pyrazolo[3,4-D]Pyrimidine Analogues of Purin-2,6-Diamine and Their Uses |
| 01/27/2011 | US20110020951 Purified sr-p70 protein |
| 01/27/2011 | US20110020928 Immunovectors which can be used for the intracellular and intranuclear transport |
| 01/27/2011 | US20110020467 Inhibition of Biogenic Sulfide Production Via Biocide and Metabolic Inhibitor Combination |
| 01/27/2011 | US20110020444 Abuse-resistant opioid dosage form |
| 01/27/2011 | US20110020420 Variable Density Tissue Graft Composition and Methods of Making and Using the Same |
| 01/27/2011 | US20110020352 Endogenous retroviruses up-regulated in prostate cancer |
| 01/27/2011 | US20110020324 Compound capable of binding s1p receptor and pharmaceutical use thereof |
| 01/27/2011 | US20110020321 Methods and compositions for using mhc class ii invariant chain polypeptide as a receptor for macrophage migration inhibitory factor |
| 01/27/2011 | US20110020306 Probiotic, Lactic Acid-Producing Bacteria and Uses Thereof |
| 01/27/2011 | US20110020305 Probiotic, Lactic Acid-Producing Bacteria and Uses Thereof |
| 01/27/2011 | US20110020295 Pre-transplant accommodated organs resistant to anti-donor immunity |
| 01/27/2011 | US20110020267 Tweak receptor |
| 01/27/2011 | US20110020264 Method and Composition for the Treatment of Scars |
| 01/27/2011 | US20110020234 Rna interference mediating small rna molecules |
| 01/27/2011 | US20110020229 Multi-Component Biological Transport Systems |
| 01/27/2011 | US20110020222 Modified antibodies and methods of use |
| 01/27/2011 | DE102009028015A1 Use of composition comprising proteasome inhibitor, nucleoside analog and interferon for producing an agent for treating hepatitis-C infection, and for treating against interferon and nucleoside analog resistant hepatitis-C virus infection |
| 01/27/2011 | CA2769133A1 Cell protection in dialysis patients by administration of a creatine compound |
| 01/27/2011 | CA2768631A1 Combination therapies with ck2 modulators |
| 01/27/2011 | CA2768301A1 Universal microbial diagnosis, detection, quantification, and specimen-targeted therapy |
| 01/26/2011 | EP2277920A2 Inhibitors of complement activation |
| 01/26/2011 | EP2277919A1 Treatment with anti-ERBB2 antibodies |
| 01/26/2011 | EP2277917A2 B7-H3L cell surface target and a family of antibodies recognizing that target |
| 01/26/2011 | EP2277907A2 Differential in tumour gene products and use of same |
| 01/26/2011 | EP2277906A2 Differential in tumour gene products and use of same |
| 01/26/2011 | EP2277905A2 Differential in tumour gene products and use of same |
| 01/26/2011 | EP2277904A2 Differential in tumour gene products and use of same |
| 01/26/2011 | EP2277903A2 Differential in tumour gene products and use of same |
| 01/26/2011 | EP2277902A2 Differential in tumour gene products and use of same |
| 01/26/2011 | EP2277901A2 Differential in tumour gene products and use of same |
| 01/26/2011 | EP2277893A2 Compounds and methods for treatment and diagnosis of chlamydial infection |
| 01/26/2011 | EP2277892A2 Compounds and methods for treatment and diagnosis of chlamydial infection |